Skip to main content

STAQUIS (Pfizer Australia Pty Ltd)

Product name
STAQUIS
Date registered
Evaluation commenced
Decision date
Approval time
249 working days (255)
Active ingredients
crisaborole
Registration type
NCE/NBE
Indication

STAQUIS (2% w/w ointment) is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.

Help us improve the Therapeutic Goods Administration site